Proteins kinase Cε is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes

被引:34
作者
Caino, M. C. [1 ]
Lopez-Haber, C. [1 ]
Kim, J. [2 ]
Mochly-Rosen, D. [3 ]
Kazanietz, M. G. [1 ]
机构
[1] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
[2] Stanford Sch Med, Stanford Comprehens Canc Ctr, Stanford, CA USA
[3] Stanford Sch Med, Dept Chem & Syst Biol, Stanford, CA USA
关键词
PKC epsilon; non-small cell lung carcinoma; tumorigenesis; cell survival; apoptotic genes; CANCER CELLS; PKC-EPSILON; INHIBITORS; DEATH; OVEREXPRESSION; ACTIVATION; RECEPTOR; DELTA; SENESCENCE; MUTATIONS;
D O I
10.1038/onc.2011.428
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinase C (PKC)epsilon, a member of the novel PKC family, has key roles in mitogenesis and survival in normal and cancer cells. PKC epsilon is frequently overexpressed in epithelial cancers, particularly in lung cancer. Using a short-hairpin RNA approach, here we established that PKCe is required for non-small cell lung carcinoma (NSCLC) growth in vitro as well as tumor growth when inoculated into athymic mice. Moreover, sustained delivery of a PKC epsilon-selective inhibitor peptide, epsilon V1-2, reduced xenograft growth in mice. Both RNA interference depletion and pharmacological inhibition of PKCe caused a marked elevation in the number of apoptotic cells in NSCLC tumors. PKC epsilon-depleted NSCLC cells show elevated expression of pro-apoptotic proteins of the Bcl2 family, caspase recruitment domain-containing proteins and tumor necrosis factor ligands/receptor superfamily members. Moreover, a Gene Set Enrichment Analysis revealed that a vast majority of the genes changed in PKC epsilon-depleted cells were also deregulated in human NSCLC. Our results strongly suggest that PKC epsilon is required for NSCLC cell survival and maintenance of NSCLC tumor growth. Therefore, PKC epsilon may represent an attractive therapeutic target for NSCLC. Oncogene (2012) 31, 2593-2600; doi:10.1038/onc.2011.428; published online 26 September 2011
引用
收藏
页码:2593 / 2600
页数:8
相关论文
共 47 条
[11]   Regulation of cell apoptosis by protein kinase c δ [J].
Brodie, C ;
Blumberg, PM .
APOPTOSIS, 2003, 8 (01) :19-27
[12]   Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic [J].
Budas, G. R. ;
Koyanagi, T. ;
Churchill, E. N. ;
Mochly-Rosen, D. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :1021-1026
[13]   Differential Regulation of Gene Expression by Protein Kinase C Isozymes as Determined by Genome-wide Expression Analysis [J].
Caino, M. Cecilia ;
von Burstin, Vivian A. ;
Lopez-Haber, Cynthia ;
Kazanietz, Marcelo G. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (13) :11254-11264
[14]   Hallmarks for senescence in carcinogenesis: novel signaling players [J].
Caino, M. Cecilia ;
Meshki, John ;
Kazanietz, Marcelo G. .
APOPTOSIS, 2009, 14 (04) :392-408
[15]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[16]   Inhibition of novel protein kinase Cε augments TRAIL-induced cell death in A549 lung cancer cells [J].
Felber, Matthias ;
Sonnemann, Juergen ;
Beck, James F. .
PATHOLOGY & ONCOLOGY RESEARCH, 2007, 13 (04) :295-301
[17]   RAS-TRANSFORMED CELLS - ALTERED LEVELS OF PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE AND CATABOLITES [J].
FLEISCHMAN, LF ;
CHAHWALA, SB ;
CANTLEY, L .
SCIENCE, 1986, 231 (4736) :407-410
[18]  
Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117
[19]   Protein kinase Cε: an oncogene and emerging tumor biomarker [J].
Gorin, Michael A. ;
Pan, Quintin .
MOLECULAR CANCER, 2009, 8
[20]   A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death [J].
Gray, MO ;
Karliner, JS ;
Mochly-Rosen, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) :30945-30951